Fidelity's marginal increase is routine portfolio rebalancing by a passive holder. Monitor future 13G filings for any material changes in stake size or a conversion to 13D, which would signal activist intent.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $18.89entry
- T+1 · 11d ago +0.05%α −0.26% · $18.90
- T+5 · 5d ago +5.72%α +2.43% · $19.97
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 11,941,763 common shares of NewAmsterdam Pharma (NAMS) as of September 30, 2026, representing 10.0% of shares outstanding. This is an increase from the prior filing (August 2026) which reported 11,931,218 shares (10.0%), reflecting a net addition of approximately 10,545 shares. The filing remains a passive stake with no change in control intent.
Key Financial Metrics
Key Facts
- FMR LLC (Fidelity) reported beneficial ownership of 11,941,763 shares of NewAmsterdam Pharma common stock as of September 30, 2026.
- The stake represents 10.0% of the outstanding shares.
- This is an increase of approximately 10,545 shares from the prior filing (11,931,218 shares as of June 30, 2026).
- The filing is a passive Schedule 13G/A, indicating no intent to change or influence control of the issuer.
- Fidelity Management & Research Company LLC is the entity that beneficially owns 5% or greater of the outstanding shares.
Financial Impact
Fidelity's stake increased by approximately 10,545 shares, valued at roughly $0.2M based on a $2.4B market cap and 10.0% stake (implied share price ~$20.10).
Risk Factors
- No material risks identified from this routine passive stake update.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000315066-26-002799 |
| Document: 0000315066-26-002799-index-headers.html | 0000315066-26-002799 |
| Document: 0000315066-26-002799-index.html | 0000315066-26-002799 |
| Document: 0000315066-26-002799.txt | 0000315066-26-002799 |
Track record
8 reports on NAMS
4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +7.23% at T+5 after the Sep 22, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Viewing Entry $18.89 to $18.90 Now $19.46 +3.02% ▲ +0.05% −0.26% vs SPY
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $20.93 to $18.89 Now $19.46 −7.02% ▼ −9.75% −5.34% vs SPY
- Sep 29, 20266w ago 8-K Neutral 4/10 Entry $23.81 to $24.32 Now $19.46 −18.27% ▲ +2.14% +2.35% vs SPY
- Sep 22, 20267w ago SC 13D/A Bullish 5/10 Entry $22.68 to $22.74 Now $19.46 −14.20% ▲ +0.26% +0.35% vs SPY
- Sep 15, 20268w ago Insider Buy Bullish 5/10 Entry $21.18 to $21.93 Now $19.46 −8.12% ▲ +3.54% +2.41% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $27.42 to $27.67 Now $19.46 −29.03% ▲ +0.91% +1.07% vs SPY
- Jul 24, 202616w ago 8-K Bullish 7/10 Entry $29.64 to $30.22 Now $19.46 −34.35% ▲ +1.96% +1.94% vs SPY
- Apr 8, 202631w ago Press Release Neutral 5/10 Entry $34.01 to $35.07 Now $19.46 −42.78% ▲ +3.12% +2.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers